Findings

What do systematic reviews say?

29 questions · 29 findings · 2 reviews · Kidney and Transplant

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 3.4%GRADE not reported 0 · 0%Very low 4 · 13.8%Low 24 · 82.8%Moderate 0 · 0%High 0 · 0%

Intravenous vs oral cyclophosphamide

Adverse events: all infections · SSNS in children

Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 0.14 [0.03, 0.72]
2 studies · 83 participants
Low

Intravenous vs oral cyclophosphamide

Adverse event nausea and vomiting (0 to 24 hours) · SSNS in children

It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).

1 finding from 1 review

Non‐corticosteroid immunosuppressive medications for steroid‐sensitive nephrotic syndrome in children 2020 · Cochrane Headline outcomes only
RR 4.07 [0.21, 80.51]
1 study · 47 participants
Very low

IV vs oral cyclophosphamide

Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children

IV showed no clear difference in complete remission compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1.58 [0.65, 3.85]
2 studies · 61 participants
Low

IV vs oral cyclophosphamide

Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children

IV showed no clear difference in partial remission compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1 [0.15, 6.55]
1 study · 50 participants
Low

IV vs oral cyclophosphamide

Remission · idiopathic steroid‐resistant nephrotic syndrome in children

IV showed no clear difference in continuing remission at one year compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.75 [0.19, 3.01]
1 study · 50 participants
Low

IV vs oral cyclophosphamide

Adverse events: renal insufficiency · idiopathic steroid‐resistant nephrotic syndrome in children

IV showed no clear difference in adverse events: renal insufficiency compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 0.33 [0.04, 2.99]
1 study · 50 participants
Low

IV vs oral cyclophosphamide

Adverse effects ‐ Bacterial infection clinical assessment · idiopathic steroid‐resistant nephrotic syndrome in children

It is very uncertain whether IV changes adverse events: bacterial infection compared with oral cyclophosphamide (very low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1.02 [0.1, 10.62]
2 studies · 61 participants
Very low

IV vs oral cyclophosphamide

Adverse events: Vomiting · idiopathic steroid‐resistant nephrotic syndrome in children

It is very uncertain whether IV changes adverse events: vomiting compared with oral cyclophosphamide (very low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 2.38 [0.35, 16.17]
2 studies · 61 participants
Very low

IV vs oral cyclophosphamide

Alopecia · idiopathic steroid‐resistant nephrotic syndrome in children

IV showed no clear difference in adverse events: alopecia compared with oral cyclophosphamide (low certainty).

1 finding from 1 review

Interventions for idiopathic steroid‐resistant nephrotic syndrome in children 2019 · Cochrane Headline outcomes only
RR 1.5 [0.27, 8.22]
1 study · 50 participants
Low